Institute of Medical Genetics and Applied Genomics, University Hospital of Tuebingen, Calwerstr. 7, 72076, Tuebingen, Germany.
Department of Neurology, The First Hospital of Jilin University, Changchun, People's Republic of China.
J Mol Neurosci. 2020 Jul;70(7):999-1008. doi: 10.1007/s12031-020-01490-2. Epub 2020 Feb 28.
Mutations in THAP1 (THAP domain-containing apoptosis-associated protein 1) are responsible for DYT6 dystonia. Until now, more than eighty different mutations in THAP1 gene have been found in patients with primary dystonia, and two third of them are missense mutations. The potential pathogeneses of these missense mutations in human are largely elusive. In the present study, we generated stable transfected human neuronal cell lines expressing wild-type or mutated THAP1 proteins found in DYT6 patients. Transcriptional profiling using microarrays revealed a set of 28 common genes dysregulated in two mutated THAP1 (S21T and F81L) overexpression cell lines suggesting a common mechanism of these mutations. ChIP-seq showed that THAP1 can bind to the promoter of one of these genes, superoxide dismutase 2 (SOD2). Overexpression of THAP1 in SK-N-AS cells resulted in increased SOD2 protein expression, whereas fibroblasts from THAP1 patients have less SOD2 expression, which indicates that SOD2 is a direct target gene of THAP1. In addition, we show that some THAP1 mutations (C54Y and F81L) decrease the protein stability which might also be responsible for altered transcription regulation due to dosage insufficiency. Taking together, the current study showed different potential pathogenic mechanisms of THAP1 mutations which lead to the same consequence of DYT6 dystonia.
THAP1(THAP 结构域包含凋亡相关蛋白 1)中的突变导致 DYT6 型肌张力障碍。到目前为止,已经在原发性肌张力障碍患者的 THAP1 基因中发现了 80 多种不同的突变,其中三分之二为错义突变。这些错义突变在人类中的潜在发病机制在很大程度上难以捉摸。在本研究中,我们生成了稳定转染的人神经元细胞系,表达在 DYT6 患者中发现的野生型或突变型 THAP1 蛋白。使用微阵列进行转录谱分析揭示了两个突变型 THAP1(S21T 和 F81L)过表达细胞系中 28 个共同失调基因,表明这些突变具有共同的机制。ChIP-seq 显示 THAP1 可以结合到其中一个基因(超氧化物歧化酶 2(SOD2)的启动子上。THAP1 在 SK-N-AS 细胞中的过表达导致 SOD2 蛋白表达增加,而 THAP1 患者的成纤维细胞中 SOD2 表达较少,这表明 SOD2 是 THAP1 的直接靶基因。此外,我们还表明,一些 THAP1 突变(C54Y 和 F81L)降低了蛋白质稳定性,这也可能由于剂量不足导致转录调节改变。总之,本研究表明 THAP1 突变的不同潜在发病机制导致了相同的 DYT6 型肌张力障碍的后果。